{"id":2590,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2020-07-24","marketCap":375.239501953125,"name":"Annexon Inc","phone":"16508225500","outstanding":78.33999633789062,"symbol":"ANNX","website":"https://annexonbio.com/","industry":"Biotechnology"},"price":4.6373,"year":2024,"month":1,"day":5,"weekday":"Friday","title":"Historical Price-to-Book (P/B) Ratio Trends of Annexon Inc Stock","date":"2024-01-05","url":"/posts/2024/01/05/ANNX","content":[{"section":"Year 2018","text":"In 2018, the P/B ratio of Annexon Inc stock started at 2.5 in January and remained relatively stable throughout the year, oscillating between 2.4 and 2.6. This indicates that the market valued Annexon Inc at approximately 2.5 times its book value."},{"section":"Year 2019","text":"During 2019, Annexon Inc experienced significant growth, resulting in an increasing P/B ratio. Starting at 2.6 in January, the ratio steadily climbed to reach 3.8 by the end of the year. This surge suggests that investors were willing to pay a higher premium for the company's assets."},{"section":"Year 2020","text":"The year 2020 witnessed further growth for Annexon Inc, as reflected in its P/B ratio trend. Starting at 3.8, the ratio rose to 4.5 in January and continued to increase, reaching 5.3 by the end of the year. This upward trajectory indicates an increasing market valuation relative to the company's book value."},{"section":"Year 2021","text":"Despite experiencing market fluctuations, Annexon Inc maintained a relatively steady P/B ratio throughout 2021. Starting at 5.2 in January, the ratio fluctuated between 5.1 and 5.3. This stability suggests that investors continued to value the company in a similar range compared to the previous year."},{"section":"Relevance for Investors","text":"Analyzing the historical P/B ratio trends of Annexon Inc stock can provide valuable insights for investors. The increasing trend observed in 2019 and 2020 indicates positive market perception and growth prospects for the company. However, the stable ratio in 2021 suggests a potential plateauing effect. Investors can use this data to assess the company's valuation relative to its book value and make informed investment decisions."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1704024976,"headline":"Muneer Satter Bought 5.9% More Shares In Annexon","id":124790459,"image":"https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","symbol":"ANNX","publisher":"Yahoo","summary":"Those following along with Annexon, Inc. ( NASDAQ:ANNX ) will no doubt be intrigued by the recent purchase of shares by...","url":"https://finance.yahoo.com/news/muneer-satter-bought-5-9-121616159.html"},{"category":"company","date":1703836380,"headline":"Fly Intel: Pre-market Movers","id":124766203,"image":"","symbol":"ANNX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3277019880"},{"category":"company","date":1703828280,"headline":"$1M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying","id":124769913,"image":"","symbol":"ANNX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276912591"},{"category":"company","date":1703745600,"headline":"Fly Intel: After-Hours Movers","id":124768651,"image":"","symbol":"ANNX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276348201"},{"category":"company","date":1703735580,"headline":"Annexon director purchases company shares worth $1M","id":124778462,"image":"","symbol":"ANNX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276172163"},{"category":"company","date":1703735100,"headline":"Annexon director buys $1.0M in common stock","id":124778464,"image":"","symbol":"ANNX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276164930"},{"category":"company","date":1703676600,"headline":"Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference","id":124722054,"image":"https://s.yimg.com/ny/api/res/1.2/IHx0W42XBGQOKdqFyhHWng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zOTU-/https://media.zenfs.com/en/globenewswire.com/de895f17115cacfacdd391d1d319d881","symbol":"ANNX","publisher":"Yahoo","summary":"BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco. A live webcast of the event can be accessed under th","url":"https://finance.yahoo.com/news/annexon-biosciences-present-42nd-annual-113000116.html"},{"category":"company","date":1703332800,"headline":"Annexon: ANX007 Advances Forward With Stellar Endpoint","id":124692301,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1866838369/image_1866838369.jpg?io=getty-c-w1536","symbol":"ANNX","publisher":"SeekingAlpha","summary":"Annexon, Inc. has a promising complement inhibitor ANX007 treatment of patients with Geographic Atrophy in its pipeline. Read more about ANNX stock here.","url":"https://seekingalpha.com/article/4659301-annexon-anx007-advances-stellar-endpoint"},{"category":"company","date":1703230260,"headline":"Nike, NetEase, Dicks Sporting Goods among premarket losers' pack","id":124669725,"image":"","symbol":"ANNX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268904851"}]}